IRVINE, Calif.--(EON: Enhanced Online News)--Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (Nasdaq: PETX). Investors who purchased or otherwise acquired Aratana shares between March 16, 2015 and February 3, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 7, 2017 lead plaintiff motion deadline.
“now anticipates that ENTYCE … will be commercially available by late 2017”
If you purchased shares of Aratana during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at email@example.com.
On February 6, 2017, Aratana revealed that the Center for Veterinary Medicine (“CVM”) had requested more information about ENTYCE, its appetite stimulation drug. Aratana informed investors that it “now anticipates that ENTYCE … will be commercially available by late 2017” and that the CVM's demand was “in connection with the Company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale.” When this information was released to the public, the value of Aratana stock fell, causing investors severe harm.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
If you wish to learn more about this lawsuit at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.